FUNDACIO PRIVADA INSTITUT DE RECERCA SOBRE IMMUNOPATOLOGIES-CAIXA, IRSICAIXA

Their core work

IrsiCaixa is a Barcelona-based research institute specializing in HIV/AIDS immunology, vaccine development, and viral reservoir characterization. Their core scientific work focuses on understanding HIV infection mechanisms, developing therapeutic and preventive vaccines, and investigating the interplay between the gut microbiome and immune response. Beyond virology, they actively engage in science-society initiatives — running science shops, citizen science programs, and participatory research projects that bridge biomedical research with community needs. They also contribute to EU food systems policy through multi-stakeholder dialogue platforms.

What they specialise in

How they've shifted over time

IrsiCaixa's early H2020 work (2015–2018) combined traditional HIV vaccine research with a strong commitment to participatory science — citizen engagement, science shops, community knowledge exchange, and responsible research curricula. From 2019 onward, their focus sharpened toward molecular and computational immunology: gut microbiome-immune interactions, inflammaging biomarkers, and systems biology approaches to HIV. This shift from community-facing science engagement toward data-intensive biomedical research marks a clear maturation toward mechanistic, translational immunology.

IrsiCaixa is moving toward computational and microbiome-driven immunology, making them an increasingly relevant partner for projects combining multi-omics data with clinical HIV and inflammation research.

How they like to work

IrsiCaixa operates primarily as a consortium partner (6 of 8 projects), but has demonstrated coordination capacity in two projects — notably MISTRAL, their largest grant at EUR 3.8M. With 91 unique partners across 26 countries, they maintain a broad and diverse network rather than relying on a small set of repeat collaborators. This profile suggests an organization comfortable contributing specialist expertise to large consortia while being capable of leading focused research efforts when the topic aligns with their core HIV/immunology mission.

IrsiCaixa has collaborated with 91 distinct partners across 26 countries, indicating a well-connected European network with global reach — consistent with the international nature of HIV/AIDS and global health research.

What sets them apart

IrsiCaixa occupies a rare niche: deep HIV immunology expertise combined with genuine experience in participatory and community-based research. Most virology labs focus purely on bench science, but IrsiCaixa has built a parallel track in citizen engagement, science shops, and open schooling — making them unusually effective at translating complex biomedical research into societal impact. For consortium builders, this dual capability is valuable when proposals require both scientific excellence and meaningful public engagement or responsible research components.

Highlights from their portfolio

• MISTRAL
  Their largest project (EUR 3.8M) and a coordinator role — investigates microbiome-immune interactions in HIV, representing their strategic research direction toward systems biology.
• EAVI2020
  Major European AIDS vaccine consortium (EUR 2M to IrsiCaixa), spanning 7 years — demonstrates sustained involvement in flagship HIV vaccine efforts.
• InSPIRES
  Unusual for a virology institute — a science-society project on participatory research, global health, and migration, showing their breadth beyond the lab.